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Adrenocortical carcinoma is a rare tumour with high malignancy and poor prognosis. This tumour is rarely diagnosed 
in the reproductive age. Complete surgical resection is the only curative treatment for adrenal cancer in all stages. After 
surgery adjuvant chemotherapy is required. Mitotane is the most important drug in adrenal cancer chemotherapy. 
Mitotane’s mode of action is not entirely explained. Animal studies 
have shown that the substance exerts a direct cytotoxic effect on 
the cells of the adrenal cortex. This activity is selective, progressive 
and affects only the zona reticularis and fasciculata of the adrenal 
cortex. Mitotane inhibits cortisol synthesis by disrupting the chain 
of cholesterol. It has been suggested, that mitotane also affects the 
peripheral metabolism of steroids, especially of transcortin (CBG). 
This results in an increase of CBG blood concentration and a reduc-
tion of the amount of free hormones.
During adrenal cancer adjuvant therapy mitotane is used for 
4–5 years in the non-invasive tumours, while in the invasive stages 
the treatment is continued for life. High toxicity is the main concern 
with mitotane treatment, which may result, inter alia, from the 
coagulopathy.
A 33 year old patient underwent right-sided adrenalecto-
my because of a non-functional adrenocortical carcinoma (the 
non-invasive form). After the procedure the patient was qualified 
for corticosteroid replacement and adjuvant mitotane therapy. After 
10 months of treatment menorrhagia occurred. Transvaginal ultra-
sound (TVUS) was performed (Fig. 1). Due to irregular appearance of 
the endometrium, the patient was qualified for a hysteroscopy with 
endometrial biopsy. The histopathological result revealed simple 
endometrial hyperplasia. After this procedure, menorrhagia did not 
subside and the patient was hospitalized again with a diagnosis of 
sideropenic anemia, which required a blood transfusion and intrave-
nous and oral iron supplementation. The lowest haemoglobin (Hb) 
level was 7.5 g%. To prevent simple endometrial hyperplasia and 
associated clinical consequences, the patient was qualified for levonorgestrel-releasing intrauterine device (LNG-IUD). 
The patient was followed-up for 4 years until the end of adjuvant therapy with mitotane. At this time menorrhagia and/or 
Figure 1. TVUS performed on 10th cycle day, before 
hysteroscopy. Endometrium was thickened and 
heterogeneous.
Figure 2. TVUS performed on 10th cycle day, 12 
months after LNG-IUD removal. Normal thickness and 
echogenicity of endometrium.
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metrorrhagia were not observed. Hb values were normal, LNG-IUD tolerance was good. No influence of LNG-IUD on the 
mitotane effectiveness and tolerance has been observed.
LNG-IUD was removed 5 years after the insertion and 1 year after ending mitotane therapy. Both TVUS (Fig. 2) and 
the histopathological result of an endometrial biopsy performed 12 months after removal of the LNG-IUD were normal. 
The pathogenesis of menorrhagia during mitotane therapy may be mainly explained by influence on peripheral 
hormones metabolism, while coagulopathy only exacerbates clinical bleeding symptoms. Increased CBG binds free 
progesterone and ultimately leads to a relative hyperestrogenism. This explains the occurrence of simple endometrial 
hyperplasia 10 months after introducing adjuvant mitotane therapy, and a satisfying response to LNG-IUD treatment.
